Morin Decreases Galectin-3 Expression and Sensitizes Ovarian Cancer Cells to Cisplatin

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2018 Sep 30

PMID 30267152

Citations 14

Authors

Dominik Bieg

Daniel Sypniewski

Ewa Nowak

Ilona Bednarek

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed at evaluating whether morin (a natural flavonoid and a known inhibitor of NF-κB) can sensitize ovarian cancer cells to cisplatin by decreasing the expression of galectin-3, which is an anti-apoptotic protein regulated by NF-κB transcription factor.

Methods: To assess the possibility of augmentation the activity of cisplatin by morin, we studied the separate and the combined effect of morin and cisplatin on viability, proliferation, and apoptosis of TOV-21G (cisplatin-sensitive) and SK-OV-3 (cisplatin-resistant) ovarian cancer cells. We also analysed the effect of morin and cisplatin on galectin-3 expression at the mRNA and protein levels.

Results: We demonstrated that morin possess antitumor activity against TOV-21G and SK-OV-3 ovarian cancer cells by reducing cell viability and proliferation as well as increasing the induction of apoptosis. Co-treatment of the cells with selected concentrations of morin and cisplatin, accordingly to specific treatment approaches, reveals a synergism, which leads to sensitization of the cells to cisplatin. During this sensitization, morin significantly reduces the expression of galectin-3 at the mRNA and protein level, regardless of the presence of cisplatin.

Conclusions: Morin sensitizes TOV-21G and SK-OV-3 ovarian cancer cells to cisplatin, what is associated with a decrease of the expression of galectin-3.

Citing Articles

Modulating NLRP3 Inflammasomes in Idiopathic Pulmonary Fibrosis: A Comprehensive Review on Flavonoid-Based Interventions.

Vithalkar M, Pradhan S, Sandra K, Bharath H, Nayak Y Cell Biochem Biophys. 2025; .

PMID: 39966334 DOI: 10.1007/s12013-025-01696-4.

Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy.

Orsolic N, Jazvinscak Jembrek M Nutrients. 2024; 16(21).

PMID: 39519572 PMC: 11547968. DOI: 10.3390/nu16213741.

Selected Flavonols in Breast and Gynecological Cancer: A Systematic Review.

Wendlocha D, Krzykawski K, Mielczarek-Palacz A, Kubina R Nutrients. 2023; 15(13).

PMID: 37447264 PMC: 10346890. DOI: 10.3390/nu15132938.

Current Understanding of Flavonoids in Cancer Therapy and Prevention.

Farhan M, Rizvi A, Aatif M, Ahmad A Metabolites. 2023; 13(4).

PMID: 37110140 PMC: 10142845. DOI: 10.3390/metabo13040481.

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy.

Romagnoli A, Maracci C, DAgostino M, La Teana A, Di Marino D Cancer Drug Resist. 2022; 4(3):596-606.

PMID: 35582305 PMC: 9094073. DOI: 10.20517/cdr.2021.20.

References

Pokrywka M, Bubka M, Janik M, Pochec E, Hoja-Lukowicz D, Litynska A . Gal-3 does not suppress cisplatin-induced apoptosis in A-375 melanoma cells. Cell Biol Int. 2016; 40(4):428-38. DOI: 10.1002/cbin.10582. View

Nessa M, Beale P, Chan C, Yu J, Huq F . Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res. 2011; 31(11):3789-97. View

Li Z, Yang Z, Lapidus R, Liu X, Cullen K, Dan H . IKK phosphorylation of NF-κB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer. Am J Cancer Res. 2015; 5(10):3098-110. PMC: 4656733. View

Zhu X, Ji M, Han Y, Guo Y, Zhu W, Gao F . PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment. Int J Oncol. 2017; 50(3):835-846. DOI: 10.3892/ijo.2017.3873. View

Ataie-Kachoie P, Badar S, Morris D, Pourgholami M . Minocycline targets the NF-κB Nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer. Mol Cancer Res. 2013; 11(10):1279-91. DOI: 10.1158/1541-7786.MCR-13-0239. View

Ikegawa T, Ohtani H, Koyabu N, Juichi M, Iwase Y, Ito C . Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 2002; 177(1):89-93. DOI: 10.1016/s0304-3835(01)00761-3. View

Bijnsdorp I, Giovannetti E, Peters G . Analysis of drug interactions. Methods Mol Biol. 2011; 731:421-34. DOI: 10.1007/978-1-61779-080-5_34. View

Oishi T, Itamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M . Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2007; 17(5):1040-6. DOI: 10.1111/j.1525-1438.2007.00916.x. View

Jin H, Lee W, Eun S, Jung J, Park H, Kim G . Morin, a flavonoid from Moraceae, suppresses growth and invasion of the highly metastatic breast cancer cell line MDA-MB‑231 partly through suppression of the Akt pathway. Int J Oncol. 2014; 45(4):1629-37. DOI: 10.3892/ijo.2014.2535. View

10.

Manna S, Aggarwal R, Sethi G, Aggarwal B, Ramesh G . Morin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis. Clin Cancer Res. 2007; 13(7):2290-7. PMC: 2740379. DOI: 10.1158/1078-0432.CCR-06-2394. View

11.

Cheng Y, Huang W, Chen C, Tsai C, Wang C, Chiu W . Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun. 2011; 412(2):334-40. DOI: 10.1016/j.bbrc.2011.07.099. View

12.

Hossein G, Keshavarz M, Ahmadi S, Naderi N . Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of Galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 2014; 14(12):7561-8. DOI: 10.7314/apjcp.2013.14.12.7561. View

13.

Wongkham S, Junking M, Wongkham C, Sripa B, Chur-in S, Araki N . Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma. Cancer Sci. 2009; 100(11):2077-84. PMC: 11158674. DOI: 10.1111/j.1349-7006.2009.01304.x. View

14.

Lavra L, Ulivieri A, Rinaldo C, Dominici R, Volante M, Luciani E . Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol. 2009; 218(1):66-75. DOI: 10.1002/path.2510. View

15.

Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T . Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem. 2004; 279(22):23477-85. DOI: 10.1074/jbc.M313709200. View

16.

Samuel P, Pink R, Brooks S, Carter D . miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance. Expert Rev Anticancer Ther. 2015; 16(1):57-70. DOI: 10.1586/14737140.2016.1121107. View

17.

Luo H, Daddysman M, Rankin G, Jiang B, Chen Y . Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell Int. 2010; 10:16. PMC: 2885998. DOI: 10.1186/1475-2867-10-16. View

18.

Su Y, Huang W, Lee W, Bamodu O, Zucha M, Astuti I . Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication. Tumour Biol. 2017; 39(5):1010428317691689. DOI: 10.1177/1010428317691689. View

19.

Wei Z, He X, Kou J, Wang J, Chen L, Yao M . Renoprotective mechanisms of morin in cisplatin-induced kidney injury. Int Immunopharmacol. 2015; 28(1):500-6. DOI: 10.1016/j.intimp.2015.07.009. View

20.

Davis A, Tinker A, Friedlander M . "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?. Gynecol Oncol. 2014; 133(3):624-31. DOI: 10.1016/j.ygyno.2014.02.038. View